Remission and recovery in depression treatment.
- Published in:
- Drug Development Research, 2005, v. 65, n. 4, p. 335, doi. 10.1002/ddr.20034
- By:
- Publication type:
- Article
Works matching IS 02724391 AND DT 2005 AND VI 65 AND IP 4
Results: 13
1
2
Potential use of neurosteroids and neuroactive steroids as modulators of symptoms of depression, anxiety, and psychotic disorders.
- Published in:
- Drug Development Research, 2005, v. 65, n. 4, p. 318, doi. 10.1002/ddr.20033
- By:
- Publication type:
- Article
3
Preclinical approaches to examine novel concepts of the pathophysiology of depressive disorders: lessons learned from tree shrews.
- Published in:
- Drug Development Research, 2005, v. 65, n. 4, p. 309, doi. 10.1002/ddr.20032
- By:
- Publication type:
- Article
4
Neuropeptide Y receptors as therapeutic targets in anxiety and depression.
- Published in:
- Drug Development Research, 2005, v. 65, n. 4, p. 301, doi. 10.1002/ddr.20031
- By:
- Publication type:
- Article
5
Small molecule melanin‐concentrating hormone receptor 1 (MCH1R) antagonists as anxiolytic and antidepressive agents.
- Published in:
- Drug Development Research, 2005, v. 65, n. 4, p. 291, doi. 10.1002/ddr.20030
- By:
- Publication type:
- Article
6
Melanin‐concentrating hormone receptor 1 antagonists for the treatment of depression and anxiety.
- Published in:
- Drug Development Research, 2005, v. 65, n. 4, p. 278, doi. 10.1002/ddr.20029
- By:
- Publication type:
- Article
7
The brain renin–angiotensin system: a target for novel antidepressants and anxiolytics.
- Published in:
- Drug Development Research, 2005, v. 65, n. 4, p. 270, doi. 10.1002/ddr.20028
- By:
- Publication type:
- Article
8
Angiotensin II AT1 receptor antagonists inhibit the angiotensin‐CRF‐AVP axis and are potentially useful for the treatment of stress‐related and mood disordersThis article is a US Government work and, as such, is in the public domain in the United States of America.
- Published in:
- Drug Development Research, 2005, v. 65, n. 4, p. 237, doi. 10.1002/ddr.20027
- By:
- Publication type:
- Article
9
Galanin receptors as novel drug targets for the treatment of depression and anxiety.
- Published in:
- Drug Development Research, 2005, v. 65, n. 4, p. 227, doi. 10.1002/ddr.20026
- By:
- Publication type:
- Article
10
NBI 30775 (R121919), an orally active antagonist of the corticotropin‐releasing factor (CRF) type‐1 receptor for the treatment of anxiety and depression.
- Published in:
- Drug Development Research, 2005, v. 65, n. 4, p. 216, doi. 10.1002/ddr.20025
- By:
- Publication type:
- Article
11
Homeostasis within the corticotropin‐releasing factor system via CRF2 receptor activation: a novel approach for the treatment of anxiety.
- Published in:
- Drug Development Research, 2005, v. 65, n. 4, p. 205, doi. 10.1002/ddr.20024
- By:
- Publication type:
- Article
12
Can CRF1 receptor antagonists become antidepressant and/or anxiolytic agents?
- Published in:
- Drug Development Research, 2005, v. 65, n. 4, p. 191, doi. 10.1002/ddr.20023
- By:
- Publication type:
- Article
13
The involvement of neuropeptides in evolution, signaling, behavioral regulation and psychopathology: focus on vasopressin.
- Published in:
- Drug Development Research, 2005, v. 65, n. 4, p. 185, doi. 10.1002/ddr.20022
- By:
- Publication type:
- Article